Sei Investments CO Avadel Pharmaceuticals PLC Transaction History

Sei Investments CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 11, 2018	SELL	$6.76 - $11.7 $567 - $982	-84 Closed	0 $0
Q4 2017 Feb 08, 2018	SELL	$8.03 - $11.25 $139,079 - $194,850	-17,320 Reduced 99.52%	84 $1,000
Q3 2017 Nov 06, 2017	BUY	$8.35 - $10.5 $145,323 - $182,742	17,404	17,404 $183,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.